Eli Lilly and Company (LLY) $935.58
Eli Lilly, a pharmaceutical titan, finds itself at a critical juncture, having shed over 12% in the last three months. Is this a high-conviction dip for investors, or does more downside loom before a rebound?
52-wk High $1133.95
📌 Investment Snapshot
- LLY trades at $935.58, commanding a 40.8x P/E multiple, significantly above the S&P 500 average.
- Q4 2025 revenue reached $19.29B with EPS of $7.39, showcasing robust top and bottom-line growth.
- The company’s dominant position in the GLP-1 market for diabetes and obesity remains its primary growth engine.
- Analysts maintain a Buy consensus with a mean target of $1209.21, implying 29.25% upside.
LLY currently navigates a technical pullback, with price sitting above key support levels but not yet signaling an oversold bounce. The RSI of 39.9 prevents an immediate ‘Buy’ call, despite a strong technical confluence score of 90/100.
| 📍 Entry Zone | $895.00 or below | 🛑 Stop-Loss | $850.00 |
| 📋 Adjust If | LLY reclaims $950 with sustained volume, signaling renewed upward momentum. | ||
The Investment Case — Why Now?
Eli Lilly has seen a significant pullback over the past three months, shedding 12.8% from its highs. This correction brings the stock closer to critical support zones, making it an intriguing watch for long-term investors. The underlying fundamental story, driven by blockbuster drugs like Zepbound and Mounjaro, remains exceptionally strong, fueling robust revenue and EPS growth.
However, the lofty valuation remains a primary concern; a P/E ratio exceeding 40x demands near-perfect execution. Any unexpected regulatory hurdles or competitive pressures in its key growth markets could trigger a sharp re-rating, especially given the current moderate volatility (VIX 23.87) and rising 10Y Treasury yields (4.31%), which typically pressure high-multiple growth stocks.
🤔 With LLY’s premium valuation, how much of the future growth from its obesity and diabetes pipeline is already priced into the current share price?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Eli Lilly and Company |
| Ticker / Exchange | LLY / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | David A. Ricks |
| Founded / HQ | 1876 / Indianapolis, Indiana |
📈 Price Action & Technicals
Inside VA
A buy-side sweep at $895.61 on March 30, 2026, signals institutional interest at this critical support zone.
LLY’s price action reveals a clear downtrend since its 52-week high, with the stock trading below its 50-day SMA of $996.78. However, it currently holds above the crucial 200-day SMA at $895.76, a level that often acts as dynamic support. This suggests a potential consolidation phase, but buyers have yet to firmly take control.
The RSI at 39.9 indicates mild weakness, avoiding oversold territory, while the MACD shows a narrowing negative divergence, hinting at a potential shift in momentum. The ADX at 49.1 confirms a strong trend, with the -DI (32.8) dominating the +DI (24.1), reinforcing the current bearish bias.
Volume Profile analysis highlights a Point of Control (POC) at $1060.44, significantly above the current price, indicating substantial historical trading activity at higher levels. The Anchored VWAP from August 2025 at $901.7 provides a key reference point; the stock is trading just above this, suggesting it could retest this level.
Recent price action saw a buy-side liquidity sweep at $895.61, aligning closely with the 200-day SMA and the Anchored VWAP. This confluence of technical indicators suggests strong demand could emerge if the stock dips further into this zone. Volume is running slightly below average, indicating a lack of conviction in the current move.
Historically, when LLY’s RSI enters this neutral-weak zone after a significant pullback, it often precedes a period of sideways consolidation before a directional move. A retest of the $895-$900 support band, coupled with an increase in volume, would present a more compelling entry point.
🤔 With the -DI dominating the ADX, what specific price action or volume surge would definitively signal a reversal of the current bearish trend?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| LLY | Eli Lilly and Company | 40.8x |
| NVO | Novo Nordisk | 45.0x |
| MRK | Merck & Co. | 28.0x |
| JNJ | Johnson & Johnson | 23.5x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $19.29B | $7.39 | +24.5% (estimated) |
| Q3 2025 | $17.60B | $6.21 | +21.4% (estimated) |
| Q2 2025 | $15.56B | $6.29 | +24.5% (estimated) |
| Q1 2025 | $12.73B | $3.06 | +21.2% (estimated) |
Eli Lilly generated $0.3B in Free Cash Flow in the latest quarter, demonstrating its ability to fund operations and strategic initiatives. The company also executed $1.5B in share buybacks, signaling confidence in its intrinsic value and a commitment to shareholder returns.
🚀 Growth Drivers — What Moves the Stock
- GLP-1 Dominance 🟢 Upside Surprise — LLY’s Mounjaro and Zepbound continue to dominate the rapidly expanding GLP-1 market for diabetes and obesity, driving multi-billion dollar revenue streams and solidifying its leadership position. This segment represents a massive addressable market with significant long-term growth potential.
- Robust Pipeline 🟡 Priced In — Beyond GLP-1s, LLY boasts a deep and diversified pipeline across oncology, neuroscience, and immunology, with several late-stage candidates poised for regulatory approval. This breadth reduces reliance on any single drug and ensures sustainable future growth.
- Manufacturing Scale-Up 🟢 Upside Surprise — The company is aggressively investing in expanding its manufacturing capacity for GLP-1 drugs, addressing supply constraints and positioning itself to capture even greater market share as demand continues to surge globally.
🤔 Given the intense competition and potential for new entrants in the GLP-1 space, how sustainable is LLY’s current market dominance and pricing power?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Lilly Endowment, Inc | 92,190 |
| Vanguard Group Inc | 81,965 |
| Blackrock Inc. | 66,792 |
| PNC Financial Services Group, Inc. | 51,333 |
| State Street Corporation | 35,361 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| DOZIER ERIC | Officer | Feb 19, 2026 | Purchase | 481 |
| ALVAREZ RALPH | Director | Mar 16, 2026 | Purchase | 12 |
| LUCIANO JUAN R | Director | Mar 16, 2026 | Purchase | 16 |
| FYRWALD J. ERIK | Director | Mar 16, 2026 | Purchase | 10 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.5 |
⚠ Key Risk Factors
~$10B+ revenue at risk
~5-10% market share shift
~$2-5B R&D write-off
~2-3% margin compression
🤔 Considering the significant regulatory and competitive risks, how much of LLY’s current valuation premium is truly justified by its long-term growth trajectory?
🎯 Guidance & Wall Street View
Management has consistently provided optimistic guidance, emphasizing strong demand for its GLP-1 portfolio and confidence in its expanded manufacturing capabilities. They project double-digit revenue growth for the foreseeable future.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $1500.0 | $1209.21 | $850.0 | 29 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| B of A Securities | Buy | $1250 | Apr 2026 | Maintains |
| Guggenheim | Buy | $1280 | Mar 2026 | Maintains |
| HSBC | Reduce | $900 | Mar 2026 | Downgrade |
| RBC Capital | Outperform | $1200 | Feb 2026 | Initiates |
The analyst community overwhelmingly maintains a Buy consensus, with the average target implying nearly 30% upside from current levels. This confidence largely stems from LLY’s market-leading position in high-growth therapeutic areas.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Continued GLP-1 market expansion and LLY’s sustained dominance, exceeding current growth expectations.
- Successful pipeline execution, particularly in Alzheimer's and immunology, adding new blockbuster drugs to the portfolio.
📊 Base Case
Our base case assumes LLY maintains its strong market position in GLP-1s, with steady revenue growth and margin expansion through 2027. We project continued innovation from its pipeline, supporting a fair value around $1100-$1150.
🐻 Bear Case
- Aggressive competitive entry or significant regulatory headwinds severely impacting GLP-1 pricing and market share.
- Major clinical trial failures or unexpected safety concerns derailing key pipeline assets.
🎯 Investor Action Plan — By Profile
The current setup lacks a clear short-term catalyst for a swing trade. Stay on the sidelines until LLY tests the $895-$900 support zone with a clear bounce signal and increased volume, targeting a quick rebound to $950.
For a position trade, we recommend waiting for a deeper pullback into the $895-$900 range, aligning with the 200-day SMA and recent buy-side sweeps. Scale in gradually if this support holds, with a long-term horizon.
Long-term investors already holding LLY should maintain their positions. The fundamental growth story remains intact, and any further dips towards the $895-$900 level could present an opportunity to add to existing holdings for compounding returns.
❓ Investor FAQ — People Also Ask
Q: Why is LLY’s P/E ratio so much higher than the S&P 500 average?
LLY commands a premium valuation due to its market-leading position in high-growth therapeutic areas, particularly the GLP-1 obesity and diabetes market. Its robust pipeline and consistent double-digit revenue growth justify this higher multiple compared to the broader market.
Q: What are the key technical levels to watch for LLY?
Investors should monitor the 200-day SMA at $895.76 and the Anchored VWAP at $901.7 as critical support zones. A break below these levels could signal further downside, while a bounce from them would confirm buying interest.
Q: Is the recent insider buying a strong bullish signal?
While recent insider transactions show small purchases by directors and officers, these are often routine compensation-related buys. The 481-share purchase by Officer Eric Dozier in February is more notable, suggesting some internal confidence, but it’s not a massive, conviction-driven buy.
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#LLY #EliLilly #HealthcareStocks #Pharma #GLP1 #StockAnalysis #Investing #Veqtio